Epithelial–Mesenchymal Transition in the Resistance to Somatostatin Receptor Ligands in Acromegaly

Frontiers in Endocrinology

Berta Soldevila¹  Manel Puig-Domingo²  Joan Gil³  Mireia Jordà³ 

[1] Department of Endocrinology and Nutrition, Germans Trias i Pujol University Hospital, Badalona, Spain;Department of Medicine, Autonomous University of Barcelona, Bellaterra, Spain;Endocrine Tumours Lab, Program of Predictive and Personalized Medicine of Cancer (PMPPC), Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain;

关键词: epithelial–menchymal transition;    somatostatin analogs;    pituitary;    E-cadherin;    somatotroph adenoma;    growth hormone;   

DOI  :  10.3389/fendo.2021.646210

来源: DOAJ

【 摘 要 】

Epithelial-mesenchymal transition (EMT) is a dynamic process by which epithelial cells loss their phenotype and acquire mesenchymal traits, including increased migratory and invasive capacities. EMT is involved in physiological processes, such as embryogenesis and wound healing, and in pathological processes such as cancer, playing a pivotal role in tumor progression and metastasis. Pituitary tumors, although typically benign, can be locally invasive. Different studies have shown the association of EMT with increased tumor size and invasion in pituitary tumors, and in particular with a poor response to Somatostatin Receptor Ligands (SRLs) treatment in GH-producing pituitary tumors, the main cause of acromegaly. This review will summarize the current knowledge regarding EMT and SRLs resistance in acromegaly and, based on this relation, will suggest new biomarkers and possible therapies to SRLs resistant tumors.

【 授权许可】

Unknown